The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies
Open accessAbstract
The vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have been shown to play major roles not only in physiological but also in most pathological angiogenesis, such as cancer. VEGF belongs to the PDGF supergene family characterized by 8 conserved cysteines and functions as a homodimer structure. VEGF-A regulates angiogenesis and vascular permeability by activating 2 receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk1 in mice). On the other hand, VEGF-C/VEGF-D and their receptor, VEGFR-3 (Flt-4), mainly regulate lymphangiogenesis. The VEGF family includes other interesting variants, one of which is the virally encoded VEGF-E and another is specifically expressed in the venom of the habu snake (Trimeresurus flavoviridis). VEGFRs are distantly related to the PDGFR family; however, they are unique with respect to their structure and signaling system. Unlike members of the PDGFR family that strongly stimulate the PI3K-Akt pathway toward cell proliferation, VEGFR-2, the major signal transducer for angiogenesis, preferentially utilizes the PLCγ-PKC-MAPK pathway for signaling. The VEGF-VEGFR system is an important target for anti-angiogenic therapy in cancer and is also an attractive system for pro-angiogenic therapy in the treatment of neuronal degeneration and ischemic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, BACE1 is also responsible for ectodomain cleavage of vascular endothelial growth factor receptor 1 (VEGFR1), a receptor important in the regulation of angiogenesis and vascular permeability.”
From BACE1: More than just a β‐secretase (2022) · cites this paper as [135]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Kim, N., Kim, H. K., Lee, K., Hong, Y., Cho, J. H., Choi, J. W., Lee, J.-I., Suh, Y.-L., Ku, B. M., Eum, H. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16164-1 · Cited by 1,274
Immune phenotypic linkage between colorectal cancer and liver metastasis
Liu, Y., Zhang, Q., Xing, B., Luo, N., Gao, R., Yu, K., Hu, X., Bu, Z., Peng, J., Ren, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.013 · Cited by 451
Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
Ramakrishnan, S., Anand, V., & Roy, S. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9531-7 · Cited by 442
Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
Wang, X., Bove, A. M., Simone, G., & Ma, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599281 · Cited by 442
Circular RNA CircFndc3b modulates cardiac repair after myocardial infarction via FUS/VEGF-A axis
Garikipati, V. N. S., Verma, S. K., Cheng, Z., Liang, D., Truongcao, M. M., Cimini, M., Yue, Y., Huang, G., Wang, C., Benedict, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11777-7 · Cited by 430
Butti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0797-x · Cited by 390
Than, A., Liu, C., Chang, H., Duong, P. K., Cheung, C. M. G., Xu, C., Wang, X., & Chen, P. (2018) · Nature Communications · doi:10.1038/s41467-018-06981-w · Cited by 345
Mehta, M., Dhanjal, D. S., Paudel, K. R., Singh, B., Gupta, G., Rajeshkumar, S., Thangavelu, L., Tambuwala, M. M., Bakshi, H. A., Chellappan, D. K., et al. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00698-3 · Cited by 330
Modi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 320
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00838-y · Cited by 197
Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191
Schatkoski, V. M., Larissa do Amaral Montanheiro, T., Canuto de Menezes, B. R., Pereira, R. M., Rodrigues, K. F., Ribas, R. G., Morais da Silva, D., & Thim, G. P. (2021) · Ceramics International · doi:10.1016/j.ceramint.2020.09.213 · Cited by 180
Endothelial Cells in the Tumor Microenvironment
Sobierajska, K., Ciszewski, W. M., Sacewicz-Hofman, I., & Niewiarowska, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_6 · Cited by 179
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081786 · Cited by 161
Vetsika, E.-K., Koukos, A., & Kotsakis, A. (2019) · Cells · doi:10.3390/cells8121647 · Cited by 125
In Vitro Strategies to Vascularize 3D Physiologically Relevant Models
Dellaquila, A., Le Bao, C., Letourneur, D., & Simon‐Yarza, T. (2021) · Advanced Science · doi:10.1002/advs.202100798 · Cited by 115
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
Targeting tumour microenvironment by tyrosine kinase inhibitor
Tan, H.-Y., Wang, N., Lam, W., Guo, W., Feng, Y., & Cheng, Y.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0800-6 · Cited by 107
BACE1: More than just a β‐secretase
Taylor, H. A., Przemylska, L., Clavane, E. M., & Meakin, P. J. (2022) · Obesity Reviews · doi:10.1111/obr.13430 · Cited by 107
“Furthermore, BACE1 is also responsible for ectodomain cleavage of vascular endothelial growth factor receptor 1 (VEGFR1), a receptor important in the regulation of angiogenesis and vascular permeability.(135) Whether BACE1 can regulate adipose tissue angiogenesis in the setting of metabolic dysfunction is an interesti…”
BackgroundCurrent targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Angiogenesis and Metabolism: Entwined for Therapy Resistance
Jiménez-Valerio, G., & Casanovas, O. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.007 · Cited by 68
Wlodarczyk, L., Szelenberger, R., Cichon, N., Saluk-Bijak, J., Bijak, M., & Miller, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083949 · Cited by 51
Interpretable meta-learning of multi-omics data for survival analysis and pathway enrichment
Cho, H. J., Shu, M., Bekiranov, S., Zang, C., & Zhang, A. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad113 · Cited by 42
Neutrophils and Neutrophil-Based Drug Delivery Systems in Anti-Cancer Therapy
Wahnou, H., El Kebbaj, R., Hba, S., Ouadghiri, Z., El Faqer, O., Pinon, A., Liagre, B., Limami, Y., & Duval, R. E. (2025) · Cancers · doi:10.3390/cancers17071232 · Cited by 35
Control of angiogenesis dictated by picomolar superoxide levels
Bir, S. C., Shen, X., Kavanagh, T. J., Kevil, C. G., & Pattillo, C. B. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.015 · Cited by 30
Down-Regulation of PDCD4 Promotes Proliferation, Angiogenesis and Tumorigenesis in Glioma Cells
Pin, G., Huanting, L., Chengzhan, Z., Xinjuan, K., Yugong, F., Wei, L., Shifang, L., Zhaojian, L., Kun, H., Weicheng, Y., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.593685 · Cited by 18
“Depletion of PDCD4 Promotes Angiogenic Activity via the VEGF-STAT3 Pathway Among many of these affected cytokines/chemokines, VEGF is the key mediator of angiogenesis, which is essential for development and growth of cancer (Shibuya, 2011).”
BackgroundMostina, M., Sun, J., Sim, S. L., Ahmed, I. A., Souza‐Fonesca‐Guimaraes, F., Wolvetang, E. J., Brown, J., Kumari, S., Khosrotehrani, K., & Shafiee, A. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502108 · Cited by 17
Puranen, J., Koponen, S., Nieminen, T., Kanerva, I., Kokki, E., Toivanen, P., Urtti, A., Ylä-Herttuala, S., & Ruponen, M. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109237 · Cited by 9
Alsaedi, A. Q., Nader, M. A., El-Kashef, D. H., & Abdelmageed, M. E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572758 · Cited by 5
Metadata
- Authors
- Shibuya, M.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-10-03
- Volume
- 2
- Issue
- 12
- Pages
- 1097-1105
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2138787512
- Cited by
- 1,748
- References
- 66
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.